U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17529(AP)	**SERIAL NO.: 10/680,879**
APPLICANT: Wheeler et al	**TITLE: METHODS FOR THE TREATMENT OF NEURODEGENERATION**
FILING DATE: October 7, 2003	**GROUP: 1617**

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	CA	6,627,210	9-2003	Olejnik et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

/LS/	CB		Bartolini et al, "Aniracetam Restores Object Recognition Impaired by Age, Scopolamine, and Nucleus Basalis Lesions", Pharmacology Biochemistry and Behavior, Vol. 53, No. 2, pp. 277-283, 1996
	CC		Ogasawara et al, "Involvement of Cholinergic and GABAergic Systems in the Reversal of Memory Disruption by NS-105, a Cognition Enhancer", Pharmacology Biochemistry and Behavior, Vol. 64, No. 1, pp. 41-52, 1999
	CD		Chang et al, "Impaired and Spared Cholinergic Functions in the Hippocampus After Lesions of the Medial Septum/Vertical Limb of the Diagonal Band With 192 IgG-Saporin", HIPPOCAMPUS 14: 170-179 (2004)
	CE		McGaughy et al, "Sustained Attention Performance in Rats With Intracortical Infusions of 192 IgG-Saporin-Induced Cortical Cholinergic Deafferentation: Effects of Physotigmine and FG 7142", Behavioral Neuroscience, Vol. 112, No. 6, 1519-1525, 1998
	CF		Ramos et al, "Adrenergic Pharmacology and Cognition: Focus on the Prefrontal Cortex", Pharmacol Ther.; 113(3): 523-536, 2007 March
	CG		Avery et al, "The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Corex of Monkeys Performing a Spatial Working Memory Task", Neuropsychopharmacology, Vol. 23, No. 3, 2000
	CH		Franowicz et al, "Mutation of the α2A-Adrenoceptor Impairs Working Memory Performance and Annuls Cognitive Enhancement by Guanfacine", The Journal of Neuroscience, 22(19): 8771-8777, October 1, 2002
	CI		Friedman et al, "The Role of Norepinephrine in the Pathophysiology of Cognitive Disorders: Potential Applications to the Treatment of Cognitive Dysfunction in Schizophrenia and Alzheimer's Disease", Society of Biological Psychiatry, 1999
	CJ		Examiner D.R. Claytor, USPTO Office Action Date Mailed: 11/17/2006 and Response to this Office Action eFiled by Attorney Joel B. German on May 17, 2007 in Our Docket 17530, Serial No. 10/680,996)
	CK		Examiner D.R. Claytor, USPTO Office Action Date Mailed: July 26, 2007 and Response to this Office Action eFiled by Attorney Joel B. German on January 24, 2008 in Our Docket 17530, Serial No. 10/680,996)
	CL		Kedar, NP. Can we prevent Parkinson's and Alzheimer's disease? J Prostgrad Med 2003: 49:236-245 - **Cited by Examiner in Office Action Date Mailed July 26, 2007** in Our Docket 17530, Serial No. 10/680,996)
	CM		Walling, AD. Amyotrophic lateral sclerosis: Lou Gehrig's disease. Am Fam Phys. Vol. 59, No. 6, pages 1-11. **Cited by Examiner in Office Action Date Mailed July 26, 2007** in Our Docket 17530, Serial No. 10/680,996)
	CN		Polman et al. Drug treatment of multiple sclerosis. BMJ. Vol. 321, pgs. 490-494, 2000. **Cited by Examiner in Office Action Date Mailed July 26, 2007** in Our Docket 17530, Serial No. 10/680,996)

EXAMINER /Layla Soroush/ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.